Safety of intramuscular tixagevimab-cilgavimab (Evusheld ® ) administration in patients at risk of iatrogenic haematoma due to haematological disorders.
Jacques A J MalherbeJeanie MiskoNishani K JayawardenaMatthew D M RawlinsLaurens ManningDuncan PurtillPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
The intramuscular administration of tixagevimab-cilgavimab in patients with haematological diseases was well tolerated and was not associated with iatrogenic haematoma.
Keyphrases